# Healthcare & Pharma Sector Deep Dive

*Research: 2026-02-19*

---

## Sector Overview

Healthcare innovation + aging demographics + GLP-1 obesity drugs = massive opportunity.

**Key Themes:**
- GLP-1 / obesity
- AI drug discovery
- Medical devices
- Aging population

---

## LLY — Eli Lilly

### Company
- **Ticker:** LLY
- **Sector:** Pharmaceuticals
- **Market Cap:** ~$700B
- **HQ:** USA

### What They Do
Ozempic/Wegovy (GLP-1) = biggest drug in history. Mounjaro. Alzheimer's (Kisunla).

### Why It's Here
- **GLP-1 supercycle**
- Supply constrained
- Massive TAM
- Pipeline

### Catalysts 2026
- Supply expansion
- New indications
- Pipeline readouts

### Risks
- Competition (Novo)
- Supply
- Pricing pressure

---

## AZN — AstraZeneca

### Company
- **Ticker:** AZN
- **Sector:** Pharmaceuticals
- **Market Cap:** ~$200B
- **HQ:** UK

### What They Do
Oncology, cardiovascular, rare disease. Vaccine maker.

### Why It's Here
- Pipeline strength
- Oncology leader
- Emerging markets

### Catalysts
- Pipeline data
- Emerging markets
- Vaccines

### Risks
- Competition
- Pricing
- Currency

---

## JNJ — Johnson & Johnson

### Company
- **Ticker:** JNJ
- **Sector:** Healthcare
- **Market Cap:** ~$400B
- **HQ:** USA

### What They Do
Pharma + medtech + consumer. Diversified healthcare.

### Why It's Here
- **Diversified**
- Dividend king
- Medtech strength

### Catalysts
- Pharma pipeline
- Medical devices
- Consumer recovery

### Risks
- Litigation
- Competition
- Currency

---

## UNH — UnitedHealth

### Company
- **Ticker:** UNH
- **Sector:** Healthcare / Insurance
- **Market Cap:** ~$500B
- **HQ:** USA

### What They Do
Health insurance + Optum (services). AI in healthcare.

### Why It's Here
- **AI in healthcare**
- Optum growth
- Scale

### Catalysts
- AI integration
- Medicare growth
- Services expansion

### Risks
- Regulatory
- Pricing pressure
- Medical costs

---

## PFE — Pfizer

### Company
- **Ticker:** PFE
- **Sector:** Pharmaceuticals
- **Market Cap:** ~$150B
- **HQ:** USA

### What They Do
COVID vaccine + pharmaceuticals. Post-COVID recovery.

### Why It's Here
- COVID recovery
- Pipeline
- Valuation

### Catalysts
- Pipeline data
- New products
- Valuation

### Risks
- COVID decline
- Pipeline
- Competition

---

## REGN — Regeneron

### Company
- **Ticker:** REGN
- **Sector:** Biotechnology
- **Market Cap:** ~$100B
- **HQ:** USA

### What They Do
Antibodies, Dupixent (with Sanofi), Eylea, KEVZARA.

### Why It's Here
- **Dupixent monster**
- Strong pipeline
- AI drug discovery

### Catalysts
- Dupixent growth
- Pipeline
- Alzheimer's

### Risks
- Competition
- Pricing

---

## VRTX — Vertex

### Company
- **Ticker:** VRTX
- **Sector:** Biotechnology
- **Market Cap:** ~$120B
- **HQ:** USA

### What They Do
Cystic fibrosis. Gene editing (CRISPR).

### Why It's Here
- CF dominance
- CRISPR (with CRISPR)
- Pipeline

### Catalysts
- CF expansion
- CRISPR approval
- Pipeline

### Risks
- Competition
- Pricing

---

## MRNA — Moderna

### Company
- **Ticker:** MRNA
- **Sector:** Biotechnology
- **Market Cap:** ~$15B
- **HQ:** USA

### What They Do
mRNA platform. COVID vaccine + pipeline.

### Why It's Here
- mRNA platform
- Pipeline (cancer, flu)
- Post-COVID

### Catalysts
- Pipeline
- New products
- Partnerships

### Risks
- COVID decline
- Pipeline
- Competition

---

## ISRG — Intuitive Surgical

### Company
- **Ticker:** ISRG
- **Sector:** Medical Devices / Robotics
- **Market Cap:** ~$160B
- **HQ:** USA

### What They Do
Da Vinci surgical robots. AI-assisted surgery.

### Why It's Here
- **AI + surgery**
- Massive moat
- Growth

### Catalysts
- AI enhancements
- Single-port
- International

### Risks
- Competition
- Reimbursement
- Volume

---

## MDT — Medtronic

### Company
- **Ticker:** MDT
- **Sector:** Medical Devices
- **Market Cap:** ~$100B
- **HQ:** Ireland/USA

### What They Do
Pacemakers, insulin pumps, surgical robots (Hugo), devices.

### Why It's Here
- Diversified
- Hugo robot
- AI diagnostics

### Catalysts
- Hugo adoption
- Diabetes
- New products

### Risks
- Competition
- Pricing
- FX

---

## DNLI — Denali Therapeutics

### Company
- **Ticker:** DNLI
- **Sector:** Biotechnology
- **Market Cap:** ~$3B
- **HQ:** USA

### What They Do
Neurodegeneration. Alzheimer's, Parkinson's, ALS. Biogen partnership.

### Why It's Here
- **AI drug discovery**
- Biogen deal
- Big unmet need

### Catalysts
- Trial results
- Partnerships
- Pipeline

### Risks
- Clinical trials
- Competition
- Capital

---

## Investment Thesis

### Bull Case
- GLP-1 = $100B+ market
- AI drug discovery
- Aging demographics
- Medical innovation

### Bear Case
- Pricing pressure
- Clinical trial risk
- Regulatory

### Key Metrics to Watch
- GLP-1 sales
- Clinical trial data
- Pricing news

---

*End of Sector Research*
